Why Tilray Stock Plunged Today

Tilray shares tumbled about 10% on Monday after Friday’s Washington Post reports that President Trump was expected to sign an executive order directing the Justice Department to reschedule marijuana (from Schedule I to Schedule III) failed to materialize, prompting profit-taking by hopeful investors. Rescheduling to Schedule III would materially reduce federal restrictions—improving access to banking and other financial services for cannabis companies—but the piece stresses the market will likely remain volatile and uncomfortable until an actual EO is signed rather than on speculation.

Analysis

The immediate catalyst described is media reports in The Washington Post late last week that President Trump was expected to sign an executive order directing the Justice Department to begin rescheduling marijuana from Schedule I to Schedule III; those reports prompted sizable buying into cannabis names on Friday but the anticipated signature did not occur, and Tilray Brands (TLRY) fell roughly 10% on Monday as investors sold into the gap between rumor and confirmation. The article highlights the practical significance of rescheduling — Schedule III would group marijuana with lower-dependence drugs such as Tylenol under DEA definitions and could materially ease federal constraints that now block basic financial services for cannabis companies. Market signals in the package show a moderately negative sentiment score of -0.45 overall and a per-ticker sentiment of -0.6 for TLRY, indicating investor disappointment and heightened downside risk on speculation. Given the continuing legal patchwork across states and the author’s explicit warning not to trade on possibility alone, the piece argues the market will likely remain uncomfortable until an actual EO is signed; Motley Fool commentary also notes Tilray was not included in its top-10 Stock Advisor picks despite the company being mentioned in the article.

Key Decisions for Investors

• Avoid initiating or expanding large directional positions in Tilray or other cannabis equities based solely on press reports; wait for a signed executive order or formal DOJ/rescheduling action
• If bullish on long-term rescheduling, consider staged or modest exposure with explicit stop-losses or position sizing to manage event-driven volatility following the 10% one-day move
• Use options or hedges to protect existing cannabis equity holdings against further downside ahead of a confirmed policy action, because the article shows sentiment is tilted negative and uncertainty is high
• Monitor concrete indicators — an official White House EO, DOJ rescheduling filings, and any changes to banking access for cannabis companies — and treat those as primary buy/sell triggers rather than media speculation